|
Volumn 6, Issue 6, 2002, Pages 465-467
|
The International Sepsis Forum's controversies in sepsis: How will sepsis be treated in 2051?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIBIOTIC AGENT;
ANTICOAGULANT AGENT;
ANTIINFLAMMATORY AGENT;
CASPASE INHIBITOR;
HEPARIN;
INTERLEUKIN 10;
INTERLEUKIN 11;
INTERLEUKIN 1BETA CONVERTING ENZYME;
PENICILLIN G;
PHOSPHOTRANSFERASE;
PROBIOTIC AGENT;
PROTEIN KINASE B;
TRANSCRIPTION FACTOR;
VASODILATOR AGENT;
ANTIMICROBIAL ACTIVITY;
APOPTOSIS;
ARTICLE;
CONTROLLED STUDY;
DIAGNOSTIC APPROACH ROUTE;
DNA POLYMORPHISM;
DRUG DELIVERY SYSTEM;
GENETIC PREDISPOSITION;
HUMAN;
IATROGENIC DISEASE;
INFLAMMATION;
INTENSIVE CARE;
MICROFLORA;
MINIMALLY INVASIVE SURGERY;
MOUSE;
NONHUMAN;
PATHOPHYSIOLOGY;
PRIORITY JOURNAL;
RESUSCITATION;
SEPSIS;
TREATMENT OUTCOME;
CRITICAL CARE;
FORECASTING;
HUMANS;
SEPSIS;
|
EID: 0036893733
PISSN: 13648535
EISSN: None
Source Type: Journal
DOI: 10.1186/cc1539 Document Type: Article |
Times cited : (5)
|
References (6)
|